# Examining Deployment and Refinement of the VIOLA-AI Intracranial Hemorrhage Model Using an Interactive NeoMedSys Platform

**Korean Title:** VIOLA-AI ë‘ê°œë‚´ ì¶œí˜ˆ ëª¨ë¸ì˜ ë°°ì¹˜ ë° ê°œì„ ì— ëŒ€í•œ ì—°êµ¬: ì¸í„°ë™í‹°ë¸Œ NeoMedSys í”Œë«í¼ì„ í™œìš©í•˜ì—¬

## ğŸ“‹ ë©”íƒ€ë°ì´í„°

**Links**: [[daily/2025-09-22|2025-09-22]] [[categories/cs.AI|cs.AI]]

## ğŸ·ï¸ ì¹´í…Œê³ ë¦¬í™”ëœ í‚¤ì›Œë“œ
**ğŸš€ Evolved Concepts**: Iterative Model Refinement

## ğŸ”— ìœ ì‚¬í•œ ë…¼ë¬¸
- [[2025-09-19/Mixture of Multicenter Experts in Multimodal AI for Debiased Radiotherapy Target Delineation_20250919|Mixture of Multicenter Experts in Multimodal AI for Debiased Radiotherapy Target Delineation]] (80.9% similar)
- [[2025-09-18/ProtoMedX_ Towards Explainable Multi-Modal Prototype Learning for Bone Health Classification_20250918|ProtoMedX Towards Explainable Multi-Modal Prototype Learning for Bone Health Classification]] (80.6% similar)
- [[2025-09-19/MedVAL_ Toward Expert-Level Medical Text Validation with Language Models_20250919|MedVAL Toward Expert-Level Medical Text Validation with Language Models]] (80.2% similar)
- [[2025-09-18/Limitations of Public Chest Radiography Datasets for Artificial Intelligence_ Label Quality, Domain Shift, Bias and Evaluation Challenges_20250918|Limitations of Public Chest Radiography Datasets for Artificial Intelligence Label Quality, Domain Shift, Bias and Evaluation Challenges]] (80.2% similar)
- [[2025-09-22/From Data to Diagnosis_ A Large, Comprehensive Bone Marrow Dataset and AI Methods for Childhood Leukemia Prediction_20250922|From Data to Diagnosis A Large, Comprehensive Bone Marrow Dataset and AI Methods for Childhood Leukemia Prediction]] (80.1% similar)

## ğŸ“‹ ì €ì ì •ë³´

**Authors:** 

## ğŸ“„ Abstract (ì›ë¬¸)

arXiv:2505.09380v2 Announce Type: replace-cross 
Abstract: Background: There are many challenges and opportunities in the clinical deployment of AI tools in radiology. The current study describes a radiology software platform called NeoMedSys that can enable efficient deployment and refinements of AI models. We evaluated the feasibility and effectiveness of running NeoMedSys for three months in real-world clinical settings and focused on improvement performance of an in-house developed AI model (VIOLA-AI) designed for intracranial hemorrhage (ICH) detection.
  Methods: NeoMedSys integrates tools for deploying, testing, and optimizing AI models with a web-based medical image viewer, annotation system, and hospital-wide radiology information systems. A prospective pragmatic investigation was deployed using clinical cases of patients presenting to the largest Emergency Department in Norway (site-1) with suspected traumatic brain injury (TBI) or patients with suspected stroke (site-2). We assessed ICH classification performance as VIOLA-AI encountered new data and underwent pre-planned model retraining. Performance metrics included sensitivity, specificity, accuracy, and the area under the receiver operating characteristic curve (AUC).
  Results: NeoMedSys facilitated iterative improvements in the AI model, significantly enhancing its diagnostic accuracy. Automated bleed detection and segmentation were reviewed in near real-time to facilitate re-training VIOLA-AI. The iterative refinement process yielded a marked improvement in classification sensitivity, rising to 90.3% (from 79.2%), and specificity that reached 89.3% (from 80.7%). The bleed detection ROC analysis for the entire sample demonstrated a high area-under-the-curve (AUC) of 0.949 (from 0.873). Model refinement stages were associated with notable gains, highlighting the value of real-time radiologist feedback.

## ğŸ” Abstract (í•œê¸€ ë²ˆì—­)

arXiv:2505.09380v2 ë°œí‘œ ìœ í˜•: êµì°¨ ëŒ€ì²´  
ì´ˆë¡: ë°°ê²½: ë°©ì‚¬ì„ í•™ì—ì„œ AI ë„êµ¬ì˜ ì„ìƒ ë°°ì¹˜ì—ëŠ” ë§ì€ ë„ì „ê³¼ ê¸°íšŒê°€ ìˆìŠµë‹ˆë‹¤. ë³¸ ì—°êµ¬ëŠ” AI ëª¨ë¸ì˜ íš¨ìœ¨ì ì¸ ë°°ì¹˜ì™€ ê°œì„ ì„ ê°€ëŠ¥í•˜ê²Œ í•˜ëŠ” ë°©ì‚¬ì„ í•™ ì†Œí”„íŠ¸ì›¨ì–´ í”Œë«í¼ì¸ NeoMedSysë¥¼ ì„¤ëª…í•©ë‹ˆë‹¤. ìš°ë¦¬ëŠ” ì‹¤ì œ ì„ìƒ í™˜ê²½ì—ì„œ NeoMedSysë¥¼ 3ê°œì›” ë™ì•ˆ ìš´ì˜í•˜ì—¬ ê·¸ ì‹¤í–‰ ê°€ëŠ¥ì„±ê³¼ íš¨ê³¼ë¥¼ í‰ê°€í–ˆìœ¼ë©°, ë‘ê°œë‚´ ì¶œí˜ˆ(ICH) íƒì§€ë¥¼ ìœ„í•´ ê°œë°œëœ ìì²´ AI ëª¨ë¸(VIOLA-AI)ì˜ ì„±ëŠ¥ í–¥ìƒì— ì¤‘ì ì„ ë‘ì—ˆìŠµë‹ˆë‹¤.  
ë°©ë²•: NeoMedSysëŠ” ì›¹ ê¸°ë°˜ ì˜ë£Œ ì˜ìƒ ë·°ì–´, ì£¼ì„ ì‹œìŠ¤í…œ ë° ë³‘ì› ì „ì²´ì˜ ë°©ì‚¬ì„  ì •ë³´ ì‹œìŠ¤í…œê³¼ í•¨ê»˜ AI ëª¨ë¸ì„ ë°°í¬, í…ŒìŠ¤íŠ¸ ë° ìµœì í™”í•˜ëŠ” ë„êµ¬ë¥¼ í†µí•©í•©ë‹ˆë‹¤. ë…¸ë¥´ì›¨ì´ ìµœëŒ€ ì‘ê¸‰ì‹¤(ì‚¬ì´íŠ¸-1)ì— ì™¸ìƒì„± ë‡Œ ì†ìƒ(TBI)ì´ ì˜ì‹¬ë˜ëŠ” í™˜ì ë˜ëŠ” ë‡Œì¡¸ì¤‘ì´ ì˜ì‹¬ë˜ëŠ” í™˜ì(ì‚¬ì´íŠ¸-2)ì˜ ì„ìƒ ì‚¬ë¡€ë¥¼ ì‚¬ìš©í•˜ì—¬ ì „í–¥ì  ì‹¤ìš©ì  ì¡°ì‚¬ê°€ ìˆ˜í–‰ë˜ì—ˆìŠµë‹ˆë‹¤. VIOLA-AIê°€ ìƒˆë¡œìš´ ë°ì´í„°ë¥¼ ì ‘í•˜ê³  ì‚¬ì „ ê³„íšëœ ëª¨ë¸ ì¬í›ˆë ¨ì„ ê±°ì¹˜ë©´ì„œ ICH ë¶„ë¥˜ ì„±ëŠ¥ì„ í‰ê°€í–ˆìŠµë‹ˆë‹¤. ì„±ëŠ¥ ì§€í‘œì—ëŠ” ë¯¼ê°ë„, íŠ¹ì´ë„, ì •í™•ë„ ë° ìˆ˜ì‹ ì ì‘ë™ íŠ¹ì„± ê³¡ì„  ì•„ë˜ ë©´ì (AUC)ì´ í¬í•¨ë˜ì—ˆìŠµë‹ˆë‹¤.  
ê²°ê³¼: NeoMedSysëŠ” AI ëª¨ë¸ì˜ ë°˜ë³µì ì¸ ê°œì„ ì„ ìš©ì´í•˜ê²Œ í•˜ì—¬ ì§„ë‹¨ ì •í™•ì„±ì„ í¬ê²Œ í–¥ìƒì‹œì¼°ìŠµë‹ˆë‹¤. ìë™ ì¶œí˜ˆ ê°ì§€ ë° ì„¸ë¶„í™”ëŠ” VIOLA-AIì˜ ì¬í›ˆë ¨ì„ ìš©ì´í•˜ê²Œ í•˜ê¸° ìœ„í•´ ê±°ì˜ ì‹¤ì‹œê°„ìœ¼ë¡œ ê²€í† ë˜ì—ˆìŠµë‹ˆë‹¤. ë°˜ë³µì ì¸ ê°œì„  ê³¼ì •ì€ ë¶„ë¥˜ ë¯¼ê°ë„ë¥¼ 79.2%ì—ì„œ 90.3%ë¡œ, íŠ¹ì´ë„ë¥¼ 80.7%ì—ì„œ 89.3%ë¡œ í¬ê²Œ í–¥ìƒì‹œì¼°ìŠµë‹ˆë‹¤. ì „ì²´ ìƒ˜í”Œì— ëŒ€í•œ ì¶œí˜ˆ ê°ì§€ ROC ë¶„ì„ì€ 0.873ì—ì„œ 0.949ì˜ ë†’ì€ ê³¡ì„  ì•„ë˜ ë©´ì (AUC)ì„ ë‚˜íƒ€ëƒˆìŠµë‹ˆë‹¤. ëª¨ë¸ ê°œì„  ë‹¨ê³„ëŠ” ì‹¤ì‹œê°„ ë°©ì‚¬ì„  ì „ë¬¸ì˜ í”¼ë“œë°±ì˜ ê°€ì¹˜ë¥¼ ê°•ì¡°í•˜ë©° ì£¼ëª©í•  ë§Œí•œ ì´ë“ê³¼ ê´€ë ¨ì´ ìˆì—ˆìŠµë‹ˆë‹¤.

## ğŸ“ ìš”ì•½

ì´ ì—°êµ¬ëŠ” ë°©ì‚¬ì„ í•™ì—ì„œ AI ë„êµ¬ì˜ ì„ìƒ ë°°ì¹˜ë¥¼ ìœ„í•œ ì†Œí”„íŠ¸ì›¨ì–´ í”Œë«í¼ NeoMedSysë¥¼ ì†Œê°œí•˜ê³ , ì´ë¥¼ í†µí•´ AI ëª¨ë¸ì˜ íš¨ìœ¨ì ì¸ ë°°ì¹˜ì™€ ê°œì„ ì„ ê°€ëŠ¥í•˜ê²Œ í•©ë‹ˆë‹¤. NeoMedSysëŠ” ì›¹ ê¸°ë°˜ ì˜ë£Œ ì´ë¯¸ì§€ ë·°ì–´, ì£¼ì„ ì‹œìŠ¤í…œ, ë³‘ì› ë°©ì‚¬ì„  ì •ë³´ ì‹œìŠ¤í…œê³¼ í†µí•©ë˜ì–´ AI ëª¨ë¸ì„ ë°°í¬, í…ŒìŠ¤íŠ¸ ë° ìµœì í™”í•©ë‹ˆë‹¤. ë…¸ë¥´ì›¨ì´ì˜ ì‘ê¸‰ì‹¤ì—ì„œ 3ê°œì›”ê°„ ì‹¤í—˜ì„ í†µí•´ ë‘ê°œë‚´ ì¶œí˜ˆ(ICH) ê°ì§€ë¥¼ ìœ„í•œ VIOLA-AI ëª¨ë¸ì˜ ì„±ëŠ¥ì„ í‰ê°€í–ˆìŠµë‹ˆë‹¤. ì—°êµ¬ ê²°ê³¼, NeoMedSysëŠ” AI ëª¨ë¸ì˜ ì§„ë‹¨ ì •í™•ë„ë¥¼ í¬ê²Œ í–¥ìƒì‹œì¼°ìœ¼ë©°, ë¯¼ê°ë„ëŠ” 79.2%ì—ì„œ 90.3%ë¡œ, íŠ¹ì´ë„ëŠ” 80.7%ì—ì„œ 89.3%ë¡œ ì¦ê°€í–ˆìŠµë‹ˆë‹¤. ë˜í•œ, ROC ë¶„ì„ì—ì„œ AUCê°€ 0.873ì—ì„œ 0.949ë¡œ ê°œì„ ë˜ì—ˆìŠµë‹ˆë‹¤. ì´ ê³¼ì •ì—ì„œ ì‹¤ì‹œê°„ ë°©ì‚¬ì„  ì „ë¬¸ì˜ í”¼ë“œë°±ì´ ì¤‘ìš”í•œ ì—­í• ì„ í–ˆìŠµë‹ˆë‹¤.

## ğŸ¯ ì£¼ìš” í¬ì¸íŠ¸

- 1. NeoMedSysëŠ” AI ëª¨ë¸ì˜ íš¨ìœ¨ì ì¸ ë°°í¬ì™€ ê°œì„ ì„ ê°€ëŠ¥í•˜ê²Œ í•˜ëŠ” ë°©ì‚¬ì„ í•™ ì†Œí”„íŠ¸ì›¨ì–´ í”Œë«í¼ì…ë‹ˆë‹¤.

- 2. NeoMedSysëŠ” ì›¹ ê¸°ë°˜ ì˜ë£Œ ì´ë¯¸ì§€ ë·°ì–´, ì£¼ì„ ì‹œìŠ¤í…œ, ë³‘ì› ì „ì²´ ë°©ì‚¬ì„  ì •ë³´ ì‹œìŠ¤í…œê³¼ í†µí•©ë˜ì–´ AI ëª¨ë¸ì˜ ë°°í¬, í…ŒìŠ¤íŠ¸, ìµœì í™”ë¥¼ ì§€ì›í•©ë‹ˆë‹¤.

- 3. VIOLA-AI ëª¨ë¸ì˜ ë‘ê°œë‚´ ì¶œí˜ˆ(ICH) ê°ì§€ ì„±ëŠ¥ì€ ìƒˆë¡œìš´ ë°ì´í„°ë¥¼ í†µí•´ 90.3%ì˜ ë¯¼ê°ë„ì™€ 89.3%ì˜ íŠ¹ì´ë„ë¡œ í–¥ìƒë˜ì—ˆìŠµë‹ˆë‹¤.

- 4. NeoMedSysëŠ” ì‹¤ì‹œê°„ ë°©ì‚¬ì„  ì „ë¬¸ì˜ í”¼ë“œë°±ì„ í†µí•´ ëª¨ë¸ì˜ ì§„ë‹¨ ì •í™•ë„ë¥¼ í¬ê²Œ í–¥ìƒì‹œì¼°ìŠµë‹ˆë‹¤.

- 5. ì „ì²´ ìƒ˜í”Œì— ëŒ€í•œ ì¶œí˜ˆ ê°ì§€ ROC ë¶„ì„ì—ì„œ AUCëŠ” 0.949ë¡œ ë†’ì€ ì„±ëŠ¥ì„ ë³´ì˜€ìŠµë‹ˆë‹¤.

---

*Generated on 2025-09-22 14:47:32*